Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bmjdrc-2021-002252 http://scihub22266oqcxt.onion/10.1136/bmjdrc-2021-002252 34083248!8182749!34083248     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34083248&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       BMJ+Open+Diabetes+Res+Care 2021 ; 9 (1): ? Nephropedia Template TP {{tp|p=34083248|t=2021. Risk factors for adverse outcomes among 35 879 veterans with and without diabetes after diagnosis with COVID-19 |pdf=|usr=}}{{34083248}} gab.com Text Risk factors for adverse outcomes among 35 879 veterans with and without diabetes after diagnosis with COVID-19 JO: BMJ Open Diabetes Res Care http://www.kidney.de/pget.php?&tw=1&pmid=34083248 #FOAvip INTRODUCTION: Risk factors and mediators of associations of diabetes with COVID-19 outcomes are unclear. RESEARCH DESIGN AND METHODS: We identified all veterans receiving Department of Veterans Affairs healthcare with >/=1 positive nasal swab for SARS-CoV-2 (28 February-31 July 2020; n=35 879). We assessed associations of diabetes (with and without insulin use) with hospitalization, intensive care unit (ICU) admission, or death at 30 days, and with hazard of death until the censoring date. Among participants with diabetes (n=13 863), we examined associations of hemoglobin A1c and antihyperglycemic medication use with COVID-19 outcomes. We estimated mediation between diabetes and outcomes by comorbidities (cardiovascular disease, heart failure, and chronic kidney disease), statin or ACE inhibitor/angiotensin receptor blocker (ARB) use, and cardiac biomarkers (brain natriuretic peptide and troponin). RESULTS: Diabetes with and without insulin use was associated with greater odds of hospitalization, ICU admission, and death at 30 days, and with greater hazard of death compared with no diabetes (OR 1.73, 1.76 and 1.63, and HR 1.61; and OR 1.39, 1.49 and 1.33, and HR 1.37, respectively, all p<0.0001). Prior sulfonylurea use was associated with greater odds of hospitalization and prior insulin use with hospitalization and death among patients with diabetes; among all participants, statin use was associated with lower mortality and ARB use with lower odds of hospitalization. Cardiovascular disease-related factors mediated <20% of associations between diabetes and outcomes. CONCLUSIONS: Diabetes is independently associated with adverse outcomes from COVID-19. Associations are only partially mediated by common comorbidities. Twit Text FOAVip Risk factors for adverse outcomes among 35 879 veterans with and without diabetes after diagnosis with COVID-19 ????BMJ Open Diabetes Res Care http://www.kidney.de/pget.php?&tw=1&pmid=34083248 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34083248 #FOAvip English Wikipedia <ref>{{Cite pmid|34083248}}</ref> Risk factors for adverse outcomes among 35 879 veterans with and without diabetes after diagnosis with COVID-19 #MMPMID34083248 Wander PL; Lowy E; Beste LA; Tulloch-Palomino L; Korpak A; Peterson AC; Young BA; Boyko EJ BMJ Open Diabetes Res Care 2021[Jun]; 9 (1): ? PMID34083248show ga INTRODUCTION: Risk factors and mediators of associations of diabetes with COVID-19 outcomes are unclear. RESEARCH DESIGN AND METHODS: We identified all veterans receiving Department of Veterans Affairs healthcare with >/=1 positive nasal swab for SARS-CoV-2 (28 February-31 July 2020; n=35 879). We assessed associations of diabetes (with and without insulin use) with hospitalization, intensive care unit (ICU) admission, or death at 30 days, and with hazard of death until the censoring date. Among participants with diabetes (n=13 863), we examined associations of hemoglobin A1c and antihyperglycemic medication use with COVID-19 outcomes. We estimated mediation between diabetes and outcomes by comorbidities (cardiovascular disease, heart failure, and chronic kidney disease), statin or ACE inhibitor/angiotensin receptor blocker (ARB) use, and cardiac biomarkers (brain natriuretic peptide and troponin). RESULTS: Diabetes with and without insulin use was associated with greater odds of hospitalization, ICU admission, and death at 30 days, and with greater hazard of death compared with no diabetes (OR 1.73, 1.76 and 1.63, and HR 1.61; and OR 1.39, 1.49 and 1.33, and HR 1.37, respectively, all p<0.0001). Prior sulfonylurea use was associated with greater odds of hospitalization and prior insulin use with hospitalization and death among patients with diabetes; among all participants, statin use was associated with lower mortality and ARB use with lower odds of hospitalization. Cardiovascular disease-related factors mediated <20% of associations between diabetes and outcomes. CONCLUSIONS: Diabetes is independently associated with adverse outcomes from COVID-19. Associations are only partially mediated by common comorbidities. |*COVID-19[MESH] |*Diabetes Mellitus/drug therapy/epidemiology[MESH] |*Veterans[MESH] |Angiotensin Receptor Antagonists[MESH] |Angiotensin-Converting Enzyme Inhibitors[MESH] |Humans[MESH] |Risk Factors[MESH]Risk factors for adverse outcomes among 35 879 veterans with and witho(epmc).pdf DeepDyve Pubget Overpricing